Nykredit A S Acquires New Shares in Illumina, Inc. $ILMN

Nykredit A S bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 64,667 shares of the life sciences company’s stock, valued at approximately $11,370,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ILMN. Fiduciary Financial Advisors acquired a new position in Illumina in the second quarter valued at about $26,000. Keating Financial Advisory Services Inc. purchased a new stake in shares of Illumina in the 2nd quarter valued at approximately $32,000. Rakuten Securities Inc. acquired a new position in shares of Illumina in the 2nd quarter worth approximately $33,000. Elyxium Wealth LLC purchased a new position in shares of Illumina during the 4th quarter worth approximately $25,000. Finally, Elevation Wealth Partners LLC increased its holdings in Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Trading Down 1.6%

NASDAQ ILMN opened at $218.22 on Friday. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $231.81. The firm has a 50 day moving average of $198.42 and a two-hundred day moving average of $159.03. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $32.95 billion, a PE ratio of 40.71, a price-to-earnings-growth ratio of 3.14 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, research analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Activity

In other news, Director Keith Meister sold 457,858 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 2,062,465 shares of company stock worth $436,589,802. Corporate insiders own 2.90% of the company’s stock.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
• Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
• Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
• Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
• Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Analysts Set New Price Targets

A number of research analysts have commented on ILMN shares. Guggenheim upped their price target on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a report on Wednesday, August 5th. Wall Street Zen raised shares of Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. JPMorgan Chase & Co. upped their target price on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Barclays boosted their price target on shares of Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research note on Friday, July 31st. Nine investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $191.31.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.